Status:
COMPLETED
Efficacy of Intra-lesional Injections of Glucantime Once a Week or Twice a Week in the Treatment of Anthroponotic Cutaneous Leishmaniasis (ACL)
Lead Sponsor:
Tehran University of Medical Sciences
Collaborating Sponsors:
Mashad University of Medical Sciences
Kerman University of Medical Sciences
Conditions:
Cutaneous Leishmaniasis
Eligibility:
All Genders
9-70 years
Phase:
PHASE3
Brief Summary
Anthroponotic Cutaneous Leishmaniasis (ACL) is a parasitic disease caused by Leishmania tropica, pentavalent antimonials (sodium stibogluconate and meglumine antimoniate) have been used as a standard ...
Eligibility Criteria
Inclusion
- Parasitologically proven cases of CL based on positive smear and/or culture
- Otherwise healthy subjects on the basis of medical history.
- Age 9-70 years
- Willing to participate in the study and sign the informed consent (by the patient or his/her parent/guardian in case of younger than 18 years).
Exclusion
- Pregnant or lactating women
- Duration of lesion more than 6 months
- Number of lesions more than 4
- History of allergy to Glucantime
- Serious systemic illnesses (as judged by the physician)
- Participation in any drug trials in the last 60 days
- No indication for systemic treatment
Key Trial Info
Start Date :
May 1 2007
Trial Type :
INTERVENTIONAL
End Date :
December 1 2007
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT04340128
Start Date
May 1 2007
End Date
December 1 2007
Last Update
April 9 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CRTSDL
Tehran, Iran, 14166